On the other hand, METTL3 overexpression or FTO inhibitor (Meclofenamic acid 2, MA2) can increase m6A level of GSCs, thus inhibit GSCs growth and slow down occurrence and development of GBM [45]. Here, METTL3 is linked to glioblastoma.